💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for BioLineRx Ltd. (BLRX)
« Back to company indexBLRX Chatter Timeline
Stock Ticker for BLRX
Most Active Tweeters for BLRX
| User | Tweets |
|---|---|
| @Tickeron | 13 |
| @coreinv1 | 10 |
| @TheFortuneTell5 | 7 |
| @mediasentiment | 7 |
| @PennySearch | 6 |
Recent Tweets for BLRX
 |
@Tickeron $BLRX in -3.7% Downtrend, sliding for three consecutive days on January 24, 2022. View odds for this and other indi… https://t.co/96nuhe1swC January 25th 2022, 6:01am |
 |
@ChartMill $BLRX shows a strong growth in EPS: 49.25%. https://t.co/jOtbxZNaEz https://t.co/1bp8p2HkBh January 24th 2022, 9:01pm |
 |
@StckPro $BLRX NEW ARTICLE : BioLineRx completes enrollment in phase 1/2a trial of cancer vaccine AGI-134… https://t.co/0d2EXrQvrc January 24th 2022, 2:01pm |
 |
@MarketCurrents $BLRX - BioLineRx completes enrollment in phase 1/2a trial of cancer vaccine AGI-134 https://t.co/WEgFjie2Gq January 24th 2022, 2:01pm |
 |
@GeorgeB14941177 $BLRX BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, A… https://t.co/y33VmUALWZ January 24th 2022, 12:01pm |
 |
@investor_feed $BLRX 6-K Bioline Rx (24 Jan, 7:11am) ? BioLineRx Announces Completion of Enrollment of Phase 1/2a… https://t.co/XMTMQuwLz0 January 24th 2022, 12:01pm |
 |
@newsinthemarket BioLineRx completes enrollment in Phase Phase 1/2a study of AGI-134 $BLRX January 24th 2022, 12:01pm |
 |
@TeamofStockTra $BLRX - BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine,… https://t.co/mLNDCFMV0S January 24th 2022, 12:01pm |
 |
@AkramMSiddique $BLRX - BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine,… https://t.co/jb5zlGO49y January 24th 2022, 12:01pm |
 |
@FlashAlert_me $BLRX [15s. delayed]: Issued Press Release on January 24, 07:00:00: BioLineRx Announces Completion of Enrollment of… https://t.co/mRarE1B2k2 January 24th 2022, 12:01pm |
 |
@PennyStockNews5 $BLRX ? Sentiments: title -0.2263 | summary 0.743 Pre-Price: 1.82 | Bid: 0 | Ask: 0 Volume: 429,532 https://t.co/l0ETp9e9Sn January 24th 2022, 12:01pm |
 |
@James__BondOO7 RT @stock_titan: $BLRX BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134,… January 24th 2022, 12:01pm |
 |
@StockNewsBot2 $BLRX BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, A… https://t.co/vuT3EIQtqS January 24th 2022, 12:01pm |
 |
@stock_titan $BLRX BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, A… https://t.co/2ESrOmRvmC January 24th 2022, 12:01pm |
|
@Tickeron $BLRX in -8.96% Downtrend, sliding for three consecutive days on January 21, 2022. View odds for this and other ind… https://t.co/8bxds5aCWR January 24th 2022, 4:01am |
 |
@TheFortuneTell5 Commented on $BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends. https://t.co/5OYGITulKI January 23rd 2022, 7:01pm |
|
@TheFortuneTell5 Commented on $BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends. https://t.co/us5r3VAlAs January 23rd 2022, 10:01am |
 |
@PennySearch $BLRX HC Wainwright & Co. gave BLRX a Buy stock rating on 2021-02-23. Find top penny stocks with PennySearch bef… https://t.co/LYnZrfB0Mr January 22nd 2022, 1:01pm |
 |
@coreinv1 $BLRX do not cover patent protection nor management in corporate presentation, that's not great. Nor safety as ment… https://t.co/NG83rbanBd January 22nd 2022, 12:01pm |
 |
@Gambiste1 RT @coreinv1: $BLRX in pancreatic cancer I don't (for now) proscribe much value due to lack of durability and differentiation. Lack of deta… January 22nd 2022, 11:01am |
|
@coreinv1 $BLRX biggest issue here is only few catalysts. Pre-NDA went well. NDA submission is a bit of non-event. Only FDA r… https://t.co/9d8Xkcv33B January 22nd 2022, 11:01am |
|
@coreinv1 $BLRX also have a second drug AGI-134 that coats tumor cells with alpha-gal to make them look like foreign tissue.… https://t.co/QTkUeSua1z January 22nd 2022, 11:01am |
|
@coreinv1 $BLRX in pancreatic cancer I don't (for now) proscribe much value due to lack of durability and differentiation. La… https://t.co/1f4xixmLxx January 22nd 2022, 11:01am |
|
@coreinv1 $BLRX Motixafortide is a best-in-class CXCR4 antagonist for multiple indications. https://t.co/sS3nqNL7uX. January 22nd 2022, 11:01am |
 |
@rami__aleme RT @leandrosalama: Took 2 small losses with $CCCL and then nailed the drop from 1.4 to 1.06. Chased $BLRX a bid because the fundamentals be… January 22nd 2022, 2:01am |
 |
@Andreacocco87 $BLRX BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobiliz… https://t.co/kxWzm8ctJh January 21st 2022, 4:01pm |
|
@Tickeron $BLRX in -13.3% Downtrend, declining for three consecutive days on January 20, 2022. View odds for this and other i… https://t.co/u3J5rvz6KJ January 21st 2022, 9:01am |
|
@Tickeron How does this affect your portfolio? $BLRX price may climb as it broke lower Bollinger Band. #BioLineRx… https://t.co/lYamEcKLwK January 21st 2022, 9:01am |
|
@PennySearch $BLRX HC Wainwright & Co. gave BLRX a Buy stock rating on 2021-02-23. Find top penny stocks with PennySearch bef… https://t.co/zndJ8MgqZJ January 21st 2022, 9:01am |
|
@TheFortuneTell5 Commented on $BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends. https://t.co/C4CwvloM6y January 20th 2022, 11:01pm |
 |
@TradeWithAlerts Nice print for $BLRX Size: 260473 Price: 1.89 Amount: $492,293.97 Time: 1600 See more: https://t.co/DC99ZKy7SX Join… https://t.co/CeFC6ThoeW January 20th 2022, 9:01pm |
 |
@A1Syad $BLRX Bullish pattern forming. Chart by https://t.co/1MjnDHV7ua https://t.co/V4DyqEfd1q January 20th 2022, 6:01pm |
 |
@winTheWorld2021 @TOFIQFAZL can $blrx go to moon? January 20th 2022, 3:01pm |
|
@winTheWorld2021 @TaraBull808 Can $blrx go to moon? January 20th 2022, 3:01pm |
 |
@iiiDCP3iii Throw $BLRX on that list January 20th 2022, 3:01pm |
 |
@MaiteMerenda $BLRX Awaiting Buy Signal. Chart by https://t.co/t5kOjgsWN3 https://t.co/GrUXtDzfAu January 20th 2022, 1:01pm |
 |
@mediasentiment $BLRX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 382 January 20th 2022, 12:01pm |
|
@mediasentiment $BLRX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 381 January 20th 2022, 12:01pm |
|
@Tickeron $BLRX in Downtrend: its price expected to drop as it breaks its higher Bollinger Band on January 18, 2022. View odd… https://t.co/FygoX8B7yA January 20th 2022, 12:01pm |
|
@PennySearch $BLRX HC Wainwright & Co. gave BLRX a Buy stock rating on 2021-02-23. Find top penny stocks with PennySearch bef… https://t.co/2iYm3bsRKJ January 20th 2022, 5:01am |
|
@coreinv1 @STL_Biotech what am I missing with regards to $BLRX if you have any critical thoughts? January 19th 2022, 10:01pm |
|
@coreinv1 $BLRX mcap 92m, cash ~60m, stock 52 low, way below post p3 peak of 4.88. EV 32m? Ridiculous! Runway until 2024 curr… https://t.co/z0pQnfHxzJ January 19th 2022, 10:01pm |
|
@coreinv1 $BLRX patent protection appears to be good. Until 2029. Weird corp pres does not address this head on. A bit minor… https://t.co/EYvdhQjfpc January 19th 2022, 10:01pm |
|
@coreinv1 $BLRX this is why approval highly likely imho. Patience is only issue. https://t.co/DGLesdV0tI https://t.co/X6CaUyTReE January 19th 2022, 9:01pm |
|
@TheFortuneTell5 Commented on $BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends. https://t.co/fxWocEXfVl January 19th 2022, 7:01pm |
|
@coreinv1 $BLRX good pre-NDA meeting, filing this year, stock back to before good trial results in May 2021... doubled at $2.… https://t.co/tZsj0KDj1B January 19th 2022, 6:01pm |
 |
@thebiotechbean RT @TheFortuneTell5: Commented on $BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends. https://t.co/kzR4GV9eSd January 19th 2022, 5:01pm |
|
@TheFortuneTell5 Commented on $BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends. https://t.co/kzR4GV9eSd January 19th 2022, 5:01pm |
 |
@alerts_real RT @Gularfnm: $BLRX BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in M… January 19th 2022, 5:01pm |
|
@alerts_real RT @TheFortuneTell5: Commented on $BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends. https://t.co/o5fHabsmUG January 19th 2022, 5:01pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2022. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?